Notable Labs Ltd (NAS:NTBL)
$ 0.8 -0.01 (-1.23%) Market Cap: 7.21 Mil Enterprise Value: 967,000.00 PE Ratio: 0 PB Ratio: 0.48 GF Score: 18/100

Vascular Biogenics Ltd and Notable Labs Inc M&A Call Transcript

Feb 23, 2023 / 01:30PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the VBL Therapeutics and Notable Labs Joint Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded, and a transcript of the call will be filed by VBL with the SEC. After the presentation by VBL Therapeutics and Notable Labs, there will not be a question-and-answer session.

I would now like to hand the conference over to your moderator, Dan Ferry of LifeSci Advisors, Investor Relations consultant for the company.

Daniel Ferry
LifeSci Advisors, LLC - MD & Relationship Manager

Thank you, operator. Good morning, everyone, and welcome to today's call discussing the proposed transaction between VBL Therapeutics and Notable Labs. Today, we will provide prepared remarks and will not be taking questions. Joining me on the call are Professor Dror Harats, CEO of VBL Therapeutics; Dr. Thomas Bock, Chief Executive Officer of Notable Labs; and Joseph Wagner, PhD, Chief Scientific Officer.

Please note that in addition to this morning's press

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot